

Leonard A Valentino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7382171/publications.pdf>

Version: 2024-02-01

60
papers

3,310
citations

318942

23
h-index

214428

50
g-index

93
all docs

93
docs citations

93
times ranked

1929
citing authors

#	ARTICLE	IF	CITATIONS
1	Discussing investigational AAV gene therapy with hemophilia patients: A guide. <i>Blood Reviews</i> , 2021, 47, 100759.	2.8	40
2	Recent Advances in the Treatment of Hemophilia: A Review. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 221-235.	3.0	21
3	The 1st <sc>WFH</sc> Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world. <i>Haemophilia</i> , 2019, 25, 189-194.	1.0	31
4	Emicizumab: Review of the literature and critical appraisal. <i>Haemophilia</i> , 2019, 25, 11-20.	1.0	45
5	Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII. <i>Haemophilia</i> , 2018, 24, 570-577.	1.0	9
6	A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds. <i>Blood</i> , 2018, 132, 487-487.	0.6	41
7	Utility of a Paediatric Bleeding Questionnaire as a screening tool for von Willebrand disease in apparently healthy children. <i>Haemophilia</i> , 2015, 21, 806-811.	1.0	22
8	<sc>US</sc> Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors. <i>Haemophilia</i> , 2015, 21, 559-567.	1.0	80
9	Individualizing prophylaxis in hemophilia: a review. <i>Expert Review of Hematology</i> , 2015, 8, 237-246.	1.0	58
10	The role of Rixubisâ„¢ in the treatment of hemophilia B. <i>Immunotherapy</i> , 2014, 6, 381-394.	1.0	5
11	The first recombinant <sc>FVIII</sc> produced in human cells â€“ an update on its clinical development programme. <i>Haemophilia</i> , 2014, 20, 1-9.	1.0	32
12	<sc>ADVATE</sc> prophylaxis: <i>post hoc</i> analysis of joint bleeding episodes. <i>Haemophilia</i> , 2014, 20, 630-638.	1.0	4
13	Matrixâ€assisted laser desorption/ionization (<sc>MALDI</sc>) imaging mass spectrometry (<sc>IMS</sc>): peering into the cup of Jamshid. <i>Haemophilia</i> , 2014, 20, 304-305.	1.0	1
14	Multicentre, randomized, openâ€label study of onâ€demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. <i>Haemophilia</i> , 2014, 20, 398-406.	1.0	55
15	Hemophilia: In Review. <i>Pediatrics in Review</i> , 2013, 34, 289-295.	0.2	54
16	Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. <i>Haemophilia</i> , 2013, 19, e151-66.	1.0	6
17	Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein. <i>Blood</i> , 2013, 122, 2349-2349.	0.6	9
18	Is Bleeding In Hemophilia Really Spontaneous Or Activity Related: Analysis Of US Patient/Caregiver Data From The Hemophilia Experiences, Results and Opportunities (HERO) Study. <i>Blood</i> , 2013, 122, 2364-2364.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Vitamin D Deficiency and Osteoporosis In Hemophilia: An Underappreciated Risk. <i>Blood</i> , 2013, 122, 3593-3593.	0.6	4
20	Biologic Response and Adverse Events To Stimulate In Patients With Von Willebrand Disease. <i>Blood</i> , 2013, 122, 2365-2365.	0.6	0
21	Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study. <i>Blood</i> , 2013, 122, 2350-2350.	0.6	0
22	Pharmacokinetics Of Recombinant Factor VIII Fc Fusion Protein (rFVIIIc) in Pediatric Subjects With Hemophilia A: An Interim Analysis Of The Kids A-LONG Study. <i>Blood</i> , 2013, 122, 3609-3609.	0.6	0
23	Developing Infrastructure For International Collaborative Research In Coagulation Disorders: Coagulation Disorders Research Consortium (CDRC) and Coagulation Disorders Data and Specimen Repository (Biorepository). <i>Blood</i> , 2013, 122, 4787-4787.	0.6	0
24	Hemophilia: In Review. <i>Pediatrics in Review</i> , 2013, 34, 289-295.	0.2	28
25	Healthcare resource utilization among haemophilia A patients in the United States. <i>Haemophilia</i> , 2012, 18, 332-338.	1.0	29
26	Patient and caregiver reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE). <i>Haemophilia</i> , 2012, 18, 554-560.	1.0	10
27	A randomized comparison of two prophylaxis regimens and a paired comparison of on demand and prophylaxis treatments in hemophilia A management. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 359-367.	1.9	241
28	A preventive approach to the management of severe hemophilia A. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 185-6.	0.3	0
29	Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. <i>Haemophilia</i> , 2011, 17, 579-589.	1.0	49
30	Venous access in the management of hemophilia. <i>Blood Reviews</i> , 2011, 25, 11-15.	2.8	26
31	Recombinant FIXFc: a novel therapy for the royal disease?. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1361-1368.	1.4	11
32	Phase II Trial of Rituximab in the Treatment of Inhibitors in Congenital Hemophilia A: Results of the RICH Study. <i>Blood</i> , 2011, 118, 27-27.	0.6	2
33	A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells,. <i>Blood</i> , 2011, 118, 3309-3309.	0.6	1
34	Pharmacokinetic/Pharmacodynamic Assessment of Reformulated Recombinant Coagulation Factor IX in Adults and Children with Severe Hemophilia B. <i>Blood</i> , 2011, 118, 1190-1190.	0.6	10
35	The Biological Efficacy Profile of a Chemically Modified Recombinant Factor VIII Molecule,. <i>Blood</i> , 2011, 118, 3324-3324.	0.6	0
36	Development of a Scoring System for Assessment of Phenotypic Variability in a Mouse Model of Hemophilia A,. <i>Blood</i> , 2011, 118, 3328-3328.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia, 2010, 16, 263-271.	1.0	46
38	Novel drugs to treat hemophilia. Expert Opinion on Emerging Drugs, 2010, 15, 597-613.	1.0	7
39	Prevention of haemarthrosis in a murine model of acute joint bleeding. Haemophilia, 2009, 15, 314-319.	1.0	13
40	The application of bypassing agent prophylaxis in haemophilia A patients with inhibitors: a meeting report. Haemophilia, 2009, 15, 959-965.	1.0	11
41	Experience with a third generation recombinant factor VIII concentrate (Advate [®]) for immune tolerance induction in patients with haemophilia A. Haemophilia, 2009, 15, 718-726.	1.0	20
42	The benefits of prophylactic treatment with APCC in patients with haemophilia and high titre inhibitors: a retrospective case series. Haemophilia, 2009, 15, 733-742.	1.0	37
43	Controversies regarding the prophylactic management of adults with severe haemophilia A. Haemophilia, 2009, 15, 5-22.	1.0	19
44	Diary Observational Study in Hemophilia (DOSE): Evaluation of Enrolled Population and Overall Diary Data Capture in Congenital Hemophilia Patients with Alloantibody Inhibitors.. Blood, 2009, 114, 3484-3484.	0.6	1
45	Surgical Experience with Recombinant FVIIa (rFVIIa) in Patients with Hemophilia and Inhibitors to Factors VIII or IX.. Blood, 2009, 114, 1304-1304.	0.6	0
46	Effects of Age on the Development of Arthropathy in Mice with Hemophilia.. Blood, 2008, 112, 3393-3393.	0.6	0
47	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine, 2007, 357, 535-544.	13.9	1,681
48	Prophylactic treatment with activated prothrombin complex concentrate (FEIBA [®] 1/2) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia, 2007, 13, 249-255.	1.0	64
49	Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage. Haemophilia, 2007, 13, 10-13.	1.0	100
50	Osteopontin in Hemophilic Synovitis.. Blood, 2007, 110, 1147-1147.	0.6	4
51	Heavy metal FIX for Christmas wounds. Blood, 2006, 108, 2888-2888.	0.6	3
52	Blood safety and the choice of anti-hemophilic factor concentrate. Pediatric Blood and Cancer, 2006, 47, 245-254.	0.8	8
53	Life expectancy in hemophilia outcome. Journal of Thrombosis and Haemostasis, 2006, 4, 507-509.	1.9	61
54	Surgical excision of a giant pelvic pseudotumour in a patient with haemophilia A. Haemophilia, 2006, 12, 541-544.	1.0	29

#	ARTICLE	IF	CITATIONS
55	Digital Analysis of Vascularity in Hemophilic Synovitis.. Blood, 2006, 108, 4070-4070.	0.6	1
56	Vascularization of the Synovial Membrane in Hemophilic Synovitis.. Blood, 2006, 108, 4018-4018.	0.6	9
57	Central venous access devices in patients with hemophilia. Expert Review of Medical Devices, 2005, 2, 699-711.	1.4	13
58	Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia, 2004, 10, 280-287.	1.0	100
59	Central venous access devices in haemophilia. Haemophilia, 2004, 10, 134-146.	1.0	136
60	Pathobiology of Hemophilic Synovitis II: Synovial Cell Proliferation.. Blood, 2004, 104, 3077-3077.	0.6	0